Avenue TherapeuticsATXI
13F holders, Q2 2024 (June 30)9holders
$3.50avg. 13F price*
At the end of Q2 2024, 9 institutions reported holding Avenue Therapeutics Inc. (ATXI) in their 13F filings. The largest holders were Armistice Capital, LLC ($263K), Sabby Management, LLC ($131K) and Tower Research Capital LLC (TRC) ($11K).
- Company
- Avenue Therapeutics Inc.
- CUSIP
- 05360L403
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $407K |
| Exits | 0 | $0 |
Ownership 9 holders
| Armistice Capital, LLC | 0.01% | New | 75,000 | $263K |
| Sabby Management, LLC | 1.95% | New | 37,394 | $131K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,205 | $11K |
| UBS Group AG | 0.00% | New | 673 | $2K |
| Wells Fargo & Company | 0.00% | New | 61 | $214 |
| Emfo, LLC | 0.00% | New | 8 | $28 |
| Bank of America Corp. | 0.00% | New | 7 | $24 |
| JPMorgan Chase & Co. | 0.00% | New | 1 | $4 |
| Royal Bank of Canada | 0.00% | New | 8 | $0 |
"% of holder's portfolio" is ATXI's weight in each manager's 13F, not the share of Avenue Therapeutics Inc. the manager owns.